View Single Post
Old 06-24-2019, 01:01 PM
ActiveMSers's Avatar
ActiveMSers ActiveMSers is online now
Dave @ ActiveMSers
Join Date: Jun 2008
Location: Albuquerque, NM
Posts: 3,863
Default Emerging Evidence on the Selective Use of AHSCT in MS

Compelling evidence suggests that autologous hematopoietic stem cell transplantation may be useful in subgroups of patients with relapsing-remitting multiple sclerosis that’s considered aggressive, highly active, and treatment refractory.

By Gloria Arminio Berlinski, MS
Reviewed by Aaron Miller, MD, Professor of Neurology, Icahn School of Medicine at Mount Sinai and Medical Director at the Corinne Goldsmith Dickinson Center for Multiple Sclerosis, New York, NY

Multiple sclerosis (MS) is a chronic inflammatory disease thought to evolve from attacks by autoreactive lymphocytes on the central nervous system’s myelin sheath peptides.1 Given this widely accepted theory of MS pathophysiology, researchers have been investigating autologous hematopoietic stem cell transplantation (AHSCT) as a treatment alternative to conventional therapy, with the first reported AHSCT-MS study being initiated in 1995. Accumulating data—mostly from small, open-label studies, including just a few with long-term follow-up—point to this procedure as primarily benefiting subgroups of patients with aggressive and highly active relapsing-remitting MS (RRMS) that’s unresponsive to established therapies.

Dave Bexfield
Reply With Quote